Skip to main content

Direct comparison of targeted MRI-guided biopsy with systematic transrectal ultrasound-guided biopsy in patients with previous negative prostate biopsies.

Kaufmann S, Kruck S, Kramer U, Gatidis S, Stenzl A, Roethke M, Scharpf M, Schilling D

Publication: Urol Int (2015) • Vol 94 • Page 319-25PMID: 25227711View on PubMed

Purpose

This paper compared prostate cancer detection in matched magnetic resonance imaging (MRI) and transrectal ultrasound (TRUS)-guided prostate biopsies from patients with at least one previously negative TRUS-guided biopsy.

Conclusion

Cancer was detected in MRI-guided cores from all 16 patients with prostate cancer but was only detected in TRUS-guided cores from 8 patients. False negatives in TRUS-guided cores were not associated with patient characteristics (mean prostate specific antigen, prostate volume, or median number of biopsies) or cancer localization.

Studies (1)

Purpose

This study compared prostate cancer detection in matched MRI and TRUS-guided prostate biopsies from patients with at least one previously negative TRUS-guided biopsy. Ten to fourteen TRUS-guided biopsies were obtained immediately following two to four MRI-guided biopsies using an 18-G biopsy gun from 35 patients with a previous negative biopsy but had elevated or rising levels of prostate specific antigen (PSA). When multiple lesions were identified, the one with the highest suspicion level was biopsied. The cancer diagnosis was determined by histologic analysis.

Summary of Findings

Prostate cancer was detected in 16 of the 35 cases, with a significantly higher prostate volume in the patients with cancer than those without (47 cm3 versus 32.5 cm3, p<0.01). Prostate cancer was detected in MRI-guided biopsies from all 16 patients with cancer but in only 8 of the matched TRUS-guided biopsies (p<0.05). Further, 88% (36 or 41) of MRI-guided cores from patients with cancer contained tumor cells, but only 8% (16 of 198) of the TRUS-guided cores contained tumor cells (p<0.001). Patient characteristics (mean PSA, PSA density, prostate volume, or median number of biopsies) were not associated with false negatives in the TRUS-guided biopsy. The majority of cores containing cancer cells were from the peripheral zone (96%) with only 2 positive biopsies (4%) obtained from the transitional zone and 49% were located in the apex as opposed to the base or mid. The localization of the positive core was not significantly different between prostate cancer cases detected in the TRUS-guided biopsies and those not detected.

  • Biospecimens

    TissueProstate
  • Preservation Types

    Formalin
  • Diagnoses

    NeoplasticBenign
    NeoplasticCarcinoma
  • Platforms

    MorphologyLight microscopy
    MorphologyH-and-E microscopy
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionBiomarker level
    4.0–25.0 ng/mL PSA
    PreaquisitionPrognostic factor
    1-4 previous biopsies
    PSA density of 0.11-0.71 ng/ml/cm3
    Prostate of 20 – 66 cm3
    Biospecimen AcquisitionBiospecimen location
    Peripheral zone
    Prostate apex
    Prostate base
    Prostate mid
    Transition zone
    Biospecimen AcquisitionMethod of tissue acquisition
    Magnetic resonance imaging-guided biopsy
    Ultrasound-guided biopsy